Microglia-driven neuroinflammatory signaling in neurodegeneration: mechanisms and therapeutic opportunities.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and therapeutic targets with no systematic methodology or primary human data.
PubMed 42313307 · doi:10.1007/s11033-026-12128-8
What was done
This narrative review summarizes the literature on microglia-driven neuroinflammatory mechanisms across major neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease. It surveys pathways involving microglial activation, astrocyte reactivity, peripheral immune infiltration, cytokine dysregulation, and blood-brain barrier breakdown, alongside potential biomarkers, computational models, and therapeutic strategies.
What was found
No quantitative data, sample sizes, or effect estimates are reported in the abstract. The review qualitatively describes chronic glial activation as a driver of synaptic loss and disease progression, discusses candidate biomarkers such as inflammatory cytokines and kynurenine metabolites, and outlines potential treatment approaches including immunomodulatory drugs, stem cells, gene editing, and nanoparticle delivery systems.
Why it matters
It provides a broad overview of neuroimmune interactions across neurodegenerative conditions, mapping out candidate biomarker classes and multi-modal therapeutic strategies.
Limits
This is a narrative review without a systematic search strategy, risk-of-bias assessment, or quantitative data synthesis. The abstract presents no original empirical measurements and notes that translating preclinical mechanistic findings into effective clinical therapies remains an ongoing challenge.
Cited by
- supports Dysregulated microglial cells can drive neuroinflammation and neurodegeneration long before clinical symptoms appear.